New Blood Test Identifies Early Metabolic Markers Predicting Brain Health and Dementia Risk

A groundbreaking study published in Nature Aging reveals that blood tests can detect metabolic fingerprints linked to brain health decades before dementia symptoms appear. Dr. Osnat Raziel, a specialist in obesity and metabolic health at Assuta Ramat Hahayal, highlights the study's potential to identify individuals at risk while their brains are still healthy, enabling early intervention.

The research analyzed nearly 1,400 metabolites in the blood of 1,082 middle-aged participants from the Rotterdam Study, none of whom had dementia at baseline. After quality control, 991 metabolites were examined for associations with cognitive performance and advanced brain MRI scans. Fourteen metabolites showed significant links to cognitive abilities, including ergothioneine, a natural antioxidant found mainly in mushrooms, and uridine compounds involved in nerve cell function. Higher levels of these were associated with better cognitive test results, while seven metabolites from environmental exposures correlated with cognitive decline.

MRI findings connected 22 metabolites to brain structure, with some linked to larger brain volume and others to white matter lesions, early indicators of brain aging and vascular damage. Notably, no significant association was found with hippocampal volume after adjustments, suggesting metabolic changes may precede classic memory-related brain damage.

The study's findings were validated in an independent cohort of 847 participants, with nine of the 14 key metabolites showing similar cognitive associations. Comparisons between metabolite profiles of cognitively healthy individuals and those who later developed Alzheimer's disease further supported their role as biological markers of brain health.

An unexpected discovery was the relationship between gut microbiome composition and brain-related metabolites, reinforcing the importance of the gut-brain axis in healthy aging. Lifestyle factors such as smoking, obesity, diabetes, and alcohol consumption significantly influenced metabolite levels, underscoring that these markers are shaped more by modifiable behaviors than genetics.

Ergothioneine emerged as a particularly important metabolite, linked to better cognitive performance and influenced by diet and possibly long-term use of acid-reducing medications, though causality remains unproven. This research marks a major advance in metabolomics, offering a detailed biological fingerprint that could one day predict risks for Alzheimer's, cardiovascular disease, and other chronic conditions years before symptoms arise.

While clinical blood tests for dementia risk are not yet available, this study points toward a future in longevity medicine focused on early detection and prevention to maintain both lifespan and quality of life. Soon, doctors may routinely assess "brain age" alongside cholesterol and glucose levels, transforming how brain health is monitored and preserved.